Posted on 4 月 30, 20244/30/24
Decoding EMA’s Blueprint on Real-World Evidence
Posted on 4 月 10, 20244/10/24
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Posted on 4 月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 5 月 20, 20205/20/20
ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access
Posted on 5 月 19, 20205/19/20
ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer
Posted on 5 月 19, 20205/19/20